- Home
- DVAX vs BST Comparison
DVAX vs BST Comparison
Compare DVAX & BST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- BST
- Stock Information
- Founded
- DVAX 1996
- BST 2014
- Country
- DVAX United States
- BST United States
- Employees
- DVAX N/A
- BST N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- BST Finance Companies
- Sector
- DVAX Health Care
- BST Finance
- Exchange
- DVAX Nasdaq
- BST Nasdaq
- Market Cap
- DVAX 1.3B
- BST 1.3B
- IPO Year
- DVAX 2004
- BST N/A
- Fundamental
- Price
- DVAX $11.36
- BST $38.94
- Analyst Decision
- DVAX Buy
- BST
- Analyst Count
- DVAX 4
- BST 0
- Target Price
- DVAX $26.25
- BST N/A
- AVG Volume (30 Days)
- DVAX 1.6M
- BST 99.2K
- Earning Date
- DVAX 08-05-2025
- BST 01-01-0001
- Dividend Yield
- DVAX N/A
- BST 7.71%
- EPS Growth
- DVAX N/A
- BST N/A
- EPS
- DVAX N/A
- BST N/A
- Revenue
- DVAX $294,620,000.00
- BST N/A
- Revenue This Year
- DVAX $21.18
- BST N/A
- Revenue Next Year
- DVAX $16.83
- BST N/A
- P/E Ratio
- DVAX N/A
- BST N/A
- Revenue Growth
- DVAX 24.76
- BST N/A
- 52 Week Low
- DVAX $9.22
- BST $27.87
- 52 Week High
- DVAX $14.63
- BST $39.59
- Technical
- Relative Strength Index (RSI)
- DVAX 66.09
- BST 67.07
- Support Level
- DVAX $10.38
- BST $38.25
- Resistance Level
- DVAX $11.48
- BST $38.85
- Average True Range (ATR)
- DVAX 0.30
- BST 0.31
- MACD
- DVAX 0.08
- BST -0.03
- Stochastic Oscillator
- DVAX 90.40
- BST 98.83
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About BST BlackRock Science and Technology Trust of Beneficial Interest
BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objective is to provide income and total return through a combination of current income, current gains, and long-term capital appreciation. It focuses on investing, under a normal market condition in equity securities of science and technology companies.